Home > Boards > US OTC > Biotechs >

VentriPoint Diagnostics Ltd. (VPTD)

Add VPTD Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/4/2015 7:59:33 AM - Followers: 11 - Board type: Free - Posts Today: 0

VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.

VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

The company's VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.

The management team executing VentriPoint's business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company's technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis.

Ventripoint Diagnostics Ltd.
100 W. Harrison St.
North Tower Unit 410
Seattle, WA 98119, United States
Phone: (206) 283-0221


Imaging the Right Ventricle

We have designed a new heart visualization system that will save you time and money. Our system is used to evaluate right heart function and does so as accurately as the current gold standard, MRI, and in a fraction of the time, resulting in better efficiency and cost savings for your hospital.

Our system was initially designed for congenital heart disease and we have approval to sale for Tetrology of Fallot and Systemic Right Hearts (d-TGAs) in both Canada and Europe. We are currently awaiting FDA approval and actively pursuing new applications such as Pulmonary Arterial Hypertension.

Angelo (VMS™), our heart visualization system, is after Michelangelo who taught his students to put dots on a page to get the proportionality correct before starting to draw an image.

Our technology uses knowledge-based reconstruction (KBR), which essentially is a library of disease specific hearts. Ultrasound images are acquired using standard clinical views (ie. Parasternal, apical, etc). After acquisition, the physician or sonographer identifies anatomical landmarks (values annulus, RV endocardium, RV Septum, etc) with dots on a number of the 2D ultrasound views through the heart. We also have a sensor (GPS) on the ultrasound probe so we know where the 2D slice (plane) is in 3D space. In this way the precise anatomical landmark is located in 3D space. Our research has proven that a constellation of 25 of these points is all that is required to define the ventricle of the heart and to allow an accurate 3D image to be constructed using KBR.

We have built a library of hearts of normal shapes and sizes as well as hearts with the particular abnormalities characteristic of the heart disease of interest. This library then becomes the catalog of possible shapes and sizes the heart can possibly be. Through a complicated regional statistical process the heart-best-shape for the 25-point constellation is selected. The resultant heart image is used to calculate heart volumes (End Diastolic/End Systolic), ejection fraction, and cardiac output. Independent research by leading cardiologists around the world has shown these calculated numbers are as accurate as MRI, CT or 3D-echo or any other way of measuring the heart.See Journals here

Our system requires about 5 minutes of acquisition time, post standard imaging protocol, and about 10-15 minutes of Dot placements. Since the Dot placements are in your control, we have created tools to help ensure you have accurate reconstructions.

From Dots to 3D

Quality Control Views:

Angelo's Advantages
  • Fast (15 minutes)
  • Convenient (same as 2D ultrasound so can be done on first visit)
  • Less expensive (compared to MRI or CT)
  • Safe (ultrasound is a very safe procedure)
  • Uses existing 2D ultrasound equipment
  • Accurate (to gold-standard MRI)
  • Easily verified for each patient (using border alignment [here] and coverage [here] )
  • Easy to learn and use by sonographers and physicians
  • Low capital cost (compared to MRI, CT or 3D echo)
  • Works on virtually everyone (high feasibility)
  • Easy to standardize between operators and hospitals
  • Generates 4-page report with all functional and Qc data as well as 3D images of the heart
  • Exported as a DICOM file, which is compatible with standard PACS archive systems
  • Generates patient history for heart analysis and plots trends
  • Analysis at remote workstation
  • Cloud-computing implementation for remote problem solving and software updates
  • Verified by independent clinical studies to be as accurate as MRI and better than 3D-echo See Journals here
  • Increases MRI productivity by off-loading cardiac MRI patients and freeing up MRI for other cases
  • Shortens waitlist times for cardiac patients requiring routine heart check ups

2D to 3D

Better sonography with integrated 2D-3D images

The Angelo (VMS™) analytics software provides composite views wherein the 2D plane transects the 3D model showing exactly where the view was taken. It has been the experience of sonographers and cardiologists that this greatly assists them in understanding the anatomy of the heart during sonography and improves their ability to obtain the correct views and excellent coverage of the heart. This is especially helpful when dealing with abnormally shaped right ventricles such as in congenital heart disease or pulmonary hypertension which often require non-standard views.


All 2D views shown in 3D reconstruction to verify coverage

The Angelo (VMS™) analysis software provides an interactive 3D view of the reconstruction along with the location of all 2D views (yellow lines) obtained from the patient study.  This image can be manipulated to verify the heart has adequate coverage to be certain that all parts of the heart have been captured.  This is a rapid quality control step for the cardiologist to have confidence in the ultrasound study as well as the resultant reconstruction and the functional parameters calculated from the study.



Fit verified by operator viewing borders on 2D views

The Angelo (VMS™) analysis system creates a 3D model of the right ventricle as defined by anatomical landmarks identified in any 2d view by placing "dots" at the correct location. Since Angelo (VMS™) has a built in GPS system, it is able to locate these anatomical landmarks in 3D space and provides this information to the algorithm that then builds the 3D model. The operator can establish how well the model fits by examining the location of the borders, shown in yellow lines, on all the 2D views within the patient study.

If the borders do not look correct, the operator can place additional dots or move the existing dots to properly locate them and then re-run the reconstruction to obtain a new model. Once the operator is satisfied with the fit, the study can be approved and ESV, EDV, EF and CO will automatically be calculated and the patient file updated.

Clinical studies have shown a 0.95 correlation to MRI - several publications confirm the same findings:
  1. Echocardiographic assessment of right ventricular volumes after surgical repair of tetralogy of fallot: clinical validation of a new echocardiographic method. Dragulescu A, Grosse-Wortmann L, Fackoury C, Riffle S, Waiss M, Jaeggi E, Yoo SJ, Friedberg MK, Mertens L. J Am Soc Echocardiogr. 2011 Nov;24(11):1191-8. Epub 2011 Sep 15.
  2. Accuracy of knowledge-based reconstruction for measurement of right ventricular volume and function in patients with tetralogy of Fallot.Sheehan FH, Kilner PJ, Sahn DJ, Vick GW 3rd, Stout KK, Ge S, Helbing WA, Lewin M, Shurman AJ, Buechel EV, Litt HI, Waiss MP. Am J Cardiol. 2010 Apr 1;105(7):993-9. Epub 2010 Feb 13.
  3. Evaluation of midwall systolic function in left ventricular hypertrophy: a comparison of 3-dimensional versus 2-dimensional echocardiographic indices. Jung HO, Sheehan FH, Bolson EL, Waiss MP, Otto CM. J Am Soc Echocardiogr. 2006 Jun;19(6):802-10.
  4. Three-dimensional visual guidance improves the accuracy of calculating right ventricular volume with two-dimensional echocardiography.Dorosz JL, Bolson EL, Waiss MS, Sheehan FH. J Am Soc Echocardiogr. 2003 Jun;16(6):675-81.

The Management Team

George Adams, CEO - B.A.Sc., M.A.Sc., Ph.D., ICD.D
  • Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010.
  • He continues as Chairman of Sernova Corp (TSXV:SVA). He was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009.
  • Dr. Adams was the President and CEO of the UT Innovations Foundation from 1999 until 2004.
  • Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service.
  • He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies.
  • Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.

Florence H. Sheehan, M.D. - Founder, Chief Scientist
  • Professor of Medicine/Cardiology at the University of Washington.
  • Twenty-seven years experience in cardiac image analysis.
  • Developed the centerline method for measuring regional ventricular function.
  • Directed the development of the CenterLine wall motion method. This method carries an FDA 510(k) and has been licensed to 15 companies, bringing in $1,466,326 to date.
  • Holds 7 patents in the field of quantitative cardiac imaging.
  • Director of the Cardiovascular Research and Training Center at the UW, which has served as the Core Laboratory for image analysis to over a dozen multi-center clinical trials.

Christine Deaton - Vice President, CFO
  • Twenty years of professional finance experience with an emphasis on gross profit improvement, cost restructuring and process re-engineering.
  • Finance Director for LexBlog - initiated budget and cash flow models to align initiatives and product roadmap. Participated in financings and Board discussions.
  • Manager of Accounting at SourceCode Technology Holdings - responsible for Business Models, International Consolidations, & KPI Dashboards leading to strong placement in Technical Workflow sector. Key in providing timely management reports for cash management. Created models and tools for revenue recognition and IFRS conversion.
  • Expertise in ERP & CRM tools, including Integrations & Implementations for emerging International technology companies.

Amol Karnick - Vice President, Sales and Business Development
  • More than eighteen years of medical imaging experience.
  • Seven years experience at GE Healthcare in various roles, including mergers and acquisitions where he helped drive $150 million in imaging sales as well as integrating 4 companies.
  • Chief Operating Officer for Sentinelle Medical Incorporated - where he was responsible for Engineering, Service, Manufacturing and Regulatory affairs.
  • General Manager at Ultrasonix Medical Corporation, where he created and led the service team and directly grew sales through business development.
  • Global expertise and experience working with multiple cultures around the world.
  • Masters in Electrical Engineering (ultrasound) from McGill University.

Scott Ashley - Vice President, Research and Development
  • Twenty-six years of core operating system software development, project management, first-line, second-line, and director experience.
  • Director of software development for HP Integrity NonStop NS16000 Server. Managed a team of over 80 software developers; operating systems, low-level millicode, compilers, debuggers, QA groups. Either directly controlled or influenced an annual division-wide budget of more than $10M.
  • Key driving force across the Tandem NonStop Division introducing quality improvement activities that reduced defect introduction rates and increased schedule accuracy.
  • Second line management responsibility for Tandem NonStop device driver development group, managing a team of 35 software developers; device driver, device diagnostics, device software quality assurance groups. Responsible for the device driver level changes across those groups for the support of the Tandem NonStop S7000 and S70000 products.
  • Manager Tandem device driver group. Responsible for rebuilding a software development group from 1 person to 8 people. Managed all software development activities supporting disk, tape, optical disk and generic SCSI devices. Drove major quality improvement project to re- write the key Tandem NonStop device driver software.

Eyal Schwartz - Chief Architect
  • Sixteen years experience leading various Software Development projects.
  • Experienced software development leader at Microsoft Corporation in the Windows, MSN, and Entertainment divisions.
  • Lead design and development of wide array of technologies including secure distributed systems, advanced user interfaces, client/server and web technologies.
  • Owner of ten U.S. patents.
  • M.S. in Computer Science from Georgia Institute of Technology

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#93   VPTDF: effective Dec. 7,2015 a one for 10 Renee 12/04/15 07:59:33 AM
#92   VPTDF: effective Dec. 7,2015 a one for 10 Renee 12/04/15 07:59:33 AM
#91   VPT halted in US & Canada "At the paulbk 10/21/15 04:07:31 PM
#90   Based on? KevinCole509 06/19/15 06:56:52 PM
#89   ***************GARBAGE STOCK****************** MONEYMADE 05/27/15 08:43:42 AM
#88   VPTDF-VPT: Ventripoint Receives Marketing Clearance from the FDA aetosellinas 05/27/15 07:02:09 AM
#87   VentriPoint GAP UP!!!! aetosellinas 05/26/15 08:14:11 AM
#86   VentriPoint Diagnostics- double digits ahead-FDA clearance will now aetosellinas 05/26/15 05:45:15 AM
#85   **VPDTF**Ventripoint Diagnostics- FDA Clearance. .10++ ahead of some aetosellinas 05/25/15 10:24:48 PM
#84   VPDTF- FDA Approval -VPT on Canadian market- US aetosellinas 05/25/15 02:31:59 PM
#83   Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased aetosellinas 05/25/15 02:31:36 PM
#82   VPT- Canada TSX- FDA!!! SEATTLE, WASHINGTON--(Marketwired - May 25, aetosellinas 05/25/15 09:42:28 AM
#81   First Patients Examined in China jesse 12/18/14 10:30:42 AM
#80   Best PR release explaining the technology I have specular 07/10/14 10:08:59 AM
#79   No need for miracle here, just patience. I'm theabbevillekid 05/17/14 08:44:22 PM
#78   good question. Wish I knew the answer whatisthecolorofmone 05/16/14 03:30:42 PM
#77   Who exactly is going to buy them out?? theabbevillekid 05/16/14 02:01:27 PM
#76   wake up people- FDA approved. Next buyout whatisthecolorofmone 03/10/14 11:52:16 AM
#75   Resubmission by Ventripoint to get its VMS system theabbevillekid 01/25/14 01:58:05 AM
#74   Nice move on Friday with decent volume. malamutus 12/14/13 10:30:01 AM
#73   Nov 25, 2013 (ACCESSWIRE via COMTEX) -- ** theabbevillekid 11/26/13 08:07:10 PM
#72   true. not dead yet. whatisthecolorofmone 11/15/13 03:04:19 PM
#71   Down today on this news but still has paulbk 11/15/13 11:45:08 AM
#70   Looks like a rising tide here...Im liking what theabbevillekid 10/17/13 09:27:13 PM
#69   VPTDF Gains Critical Support From Well-Connected Board Of Directors QualityStocks 08/07/13 02:52:03 PM
#68   VPTDF Business Model Designed for Rich Recurring Revenue QualityStocks 08/01/13 04:39:33 PM
#67   VPTDF Heart Analysis System Published in Prestigious Medical QualityStocks 07/25/13 09:00:21 AM
#66   VPTDF Connects All the Dots QualityStocks 07/23/13 12:35:19 PM
#65   Timely Heart Analysis System Positioned for Pulmonary Arterial QualityStocks 07/16/13 12:05:04 PM
#64   VPTDF Expands Target Market to Include Pulmonary Hypertension QualityStocks 07/08/13 12:21:19 PM
#63   VentriPoint Diagnostics Ltd. (VPTDF) Releases Thick Corporate Update, QualityStocks 06/24/13 09:39:39 AM
#62   VPTDF VMS™ Technology Notches Favorable Feedback Worldwide QualityStocks 06/21/13 11:09:58 AM
#61   VPTDF Seeks to Expand AngeloVMS™ Applications, Triple Sales QualityStocks 06/14/13 01:49:45 PM
#60   VPTDF Addresses Unmet Medical Need, Offers Outlook for QualityStocks 06/12/13 10:48:48 AM
#59   VPTDF Appoints New Vice-President of Sales and Marketing QualityStocks 05/30/13 04:16:50 PM
#58   VPTDF Technology Now Used by Hospitals around the World QualityStocks 05/28/13 02:47:01 PM
#57   Top Lineup for VPTDF QualityStocks 05/21/13 04:00:54 PM
#56   VPTDF and Knowledge Based Reconstruction QualityStocks 05/14/13 01:30:02 PM
#55   VPTDF Prices Private Placements of Common Stock QualityStocks 05/07/13 09:47:08 AM
#54   VPTDF and the MRI Alternative QualityStocks 05/06/13 02:04:35 PM
#53   VPTDF Receives Expanded License from Health Canada QualityStocks 04/30/13 08:23:40 AM
#52   VPTDF Reports FDA Response to 510 (k) Submission QualityStocks 04/25/13 08:42:42 AM
#51   The Case for VPTDF QualityStocks 04/24/13 12:22:34 PM
#50   CEO George Adams has posted the following blog QualityStocks 04/18/13 11:27:30 AM
#49   VPTDF Receives CE Mark for NRV™ Application, Vastly QualityStocks 04/17/13 08:41:46 AM
#48   VPTDF Changes the Way Doctors Look at Hearts QualityStocks 04/10/13 01:52:58 PM
#47   Revamped and Updated 23-Page Corporate Presentation QualityStocks 04/05/13 03:49:52 PM
#46   Busy March Sets the Stage for VPTDF QualityStocks 04/03/13 01:34:31 PM
#44   VPTDF Offers New Hope for CHD Patients QualityStocks 03/27/13 10:42:55 AM
#43   VentriPoint Diagnostics Ltd. (VPTDF) Pursues European and Canadian QualityStocks 03/21/13 08:42:28 AM